Medesis Pharma S.A.

Board/Management Information • Oct 4, 2022

MEDESIS PHARMA FURTHER STRENGTHENS ITS GOVERNANCE

TWO ENTREPRENEURS FROM THE AMERICAN HEALTH SECTOR JOIN THE SUPERVISORY BOARD STRATEGIC REVIEW OF PRIORITY PROGRAMS

Montpellier, October 4, 2022 - 8am - MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates with Aonys, its proprietary buccal nanodroplet active ingredient administration technology, will submit a proposal at the next General Meeting, scheduled for October 27, 2022, to appoint two new Supervisory Board members, Robert J. Alonso and Walt A. Linscott, Esq. Msc.

With accomplished careers developing biotechnology companies, they will enable MEDESIS PHARMA's Supervisory Board to benefit from their biotechnology company management and financing expertise and their successful experiences with the development of drug candidates on the American market.

During the Supervisory Board's working session from September 27 to 29, 2022, attended by Mr Linscott and Mr Alonso at MEDESIS PHARMA's headquarters in Montpellier, the Board carried out a strategic review of its pipeline with a view to prioritizing the development of its drug candidates and its portfolio of pharmaceutical active ingredients, focusing in particular on their potential on the North American market. In this context, various decisions were taken, such as:

• · continuing to move forward with the drug candidates for the treatment of neurodegenerative diseases (Alzheimer's, NanoLithium AZ program, Phase II clinical trial underway, Huntington's, NanosiRNA HD program, development plan for the clinical trials being prepared by €300K of funding from AFM-Téléthon1);
• · continuing to develop the collaborative research program with Transgène in oncology;
• · continuing to carry out the preclinical trials for resistant cancers with siRNAs targeting the genes and/or overexpressed oncogenes responsible for the serious forms of these cancers, looking to set up partnerships with pharmaceutical laboratories;
• · focusing on the international development potential of the nuclear decorporation treatments;
• · to end the Phase II clinical study of the NanoManganese program for the treatment of COVID-19 underway in Brazil, in view of the sharp decrease in the severity of the disease which reduces the potential for patient recruitment while the costs and obstacles to finalize it are substantial;

"I am delighted to be joining Medesis' supervisory board and look forward to helping Jean Claude and the team reach important milestones as Medesis builds for the future. Medesis' programs are unique and hopefully one day will help many millions with serious diseases that today have few good treatment options", says Robert Alonso

"It is with great enthusiasm that I join the supervisory board of MEDESIS PHARMA. I look forward to working with the team to help advance Medesis' programs and expand the reach of its technology to the global community. The Aonys plafform developed by Medesis presents an excellent opportunity to bring a variety of unique treatment approaches to underserved and unmet therapeutic needs that afflict people everywhere" stated Mr. Walt Linscott

Jean Claude Maurel, CEO, Chairman of the Executive Board and founder of MEDESIS PHARMA, concludes: "Ve are moving into a crucial new phase with these two renowned entrepreneurs joining our Supervisory Board. Their pharmaceutical market knowledge and experience, their ability to meet the challenges of developing in complex environments, and their mastery of life sciences and the American regulatory environment represent valuable assets for MEDESIS PHARMA. Our exchanges in the last few days and the decisions that we have taken have been remarkably effective. The development plan that we are working on is robust, and we will be able to accelerate our search for financing: I am confident about the future of our priority programs and our ability to effectively capitalize on our proprietary technology Aonys. I would invite our shareholders to show their widespread support for their appointment".

¹ See press release from July 20, 2022

PRESS RELEASE

The ratification of the appointment of Mr Linscott to MEDESS PHARMA's Supervisory Board will be submitted for approval by MEDESIS PHARMA's shareholders during a General Meeting, which will be convened soon and held on October 27, 2022. The Supervisory Board, chaired by Olivier Connes, will then have eight members, compared with six currently.

Robert J. Alonso, MBA

Mr Alonso has 25 years of experience with major pharmaceutical companies (Merck, Roche) and has been an entrepreneur for the last 15 years, founding several startups. Currently Mr. Alonso serves as the Founder and CEO of Mitochon Pharmaceuticals, biotech company focused on neurodegenerative diseases. Prior to Mitochon, Mr Alonso successfully founded Ceptaris There he raised over \$50m in venture capital, steered the lead program through phase III testing and filing of a new drug application (NDA), which was approved in 2013. Ceptaris was sold in 2013 to Actellion Pharmaceuticals. Mr Alonso is a seasoned executive who has completed numerous licensing and other business transactions, including raising venture capital and negotiating transactions worth over \$500m. He has brought several drugs through the FDA's Investigational New Drug (IND) process and one through a successful completion of an NDA. Mr Alonso is the inventor on nine issued patents. He has a B.S. degree from Boston College and an MBA in Entrepreneurship from Babson College.

Walt A. Linscott, Esq. MSc

Walt Linscott brings three decades of global leadership, entrepreneurial and professional experience with broad business development, operational, regulatory, and transactional experience in the Life Sciences sector to his current role as Chief Business Officer at Indaptus. Most recently, he held a similar role at Intec Pharma. He is also a Founding executive member of Oxford Strategic Alliance, a multinational business development and referral enterprise for strategic advice, management and investment development for individuals and companies that are globalizing. Previously, Walt served as President, COO and General Counsel at Treiber Therapeutics, an anti-viral focused venture he cofounded. He has also served in a variety of General Counsel and Corporate Secretary roles at Cocrystal Pharma, Carestream Health, and Solvay Pharmaceuticals, where he also led compliance, IP, security, privacy, public affairs and government affairs functions. In addition, he was previously an Associate and Partner at Thompson Hine where he founded the firm's Atlanta office, served as Partner in Charge, and as Chair of the Science Practice Group. Walt holds a Master of Science in Experimental and Translational Therapeutics with honors from the University of Oxford, a Master's degree in Global Business from the University of Oxford and Master's degree in Entrepreneurship from Cambridge University. He earned his J.D. from the University of Dayton School of Law where he served as Managing Editor of the Law Review. After graduating with a Bachelor's degree from Syracuse University and prior to entering law school, he earned a commission and served on active duty as an Officer in the United States Marine Corps.

About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB). This innovative approach is being applied for future drugs to treat major diseases that do not have effective treatments: Alzheimer's Disease, certain resistant cancers.

Medesis Pharma is also developing dedicated treatments for people contaminated or irradiated following a civil or military nuclear accident.

Medesis Pharma, a French biopharmaceutical company based near Montpellier, has a track record of 15 scientific publications, holds 11 patents, reflecting 17 years of research, and is focused specifically on four projects that are moving into Clinical Phase II for neurodegenerative diseases and the treatment of Covid-19. Building on its world-renowned positions, Medesis Pharma is also working on new applications for its technology in partnership with public research laboratories (CNRS, CEA, IRBA), major teaching hospital centers in France, Canada and the United States, as well as private structures such as Transgene.

Medesis Pharma's shares are listed on Euronext Growth Paris (FR0010844464 — ALMDP

For more information: www.medesispharma.com

MFDFSIS PHARMA Tessa Olivato

Tel: +33 4 67 03 03 96 contact@medesispharma.com

CALYPTUS

Marie Calleux Tel : +33 1 53 65 68 66 medesispharma@calyptus.net